Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressin

Yuan-Yuan Hao, Pan-Pan Chen, Xiang-Gui Yuan, Ai-Qi Zhao, Yun Liang, Hui Liu, Wen-Bin Qian

Abstract

Key Words: Chimeric antigen receptor T cell therapy; Diffuse large B-cell lymphoma; Immunotherapy; PD-1 inhibitor; Histone deacetylase inhibitor; Case report

lNTRODUCTlON

Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkins lymphoma (NHL), is the seventh most common cancer worldwide[1]. Most patients are cured with the combination of rituximab and traditional chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone [R-CHOP]). However, up to 50% of patients become refractory to treatment or relapse after treatment and these R/R DLBCL patients have a poor prognosis[2]. Recently, CD19-targeted chimeric antigen receptor T cells (CAR-T) have shown significant efficacy in patients with R/R DLBCL or another aggressive B-cell lymphoma[3,4]. In the ZUMA-1 study, patients who received CAR-T (Axi-cel) cell therapy showed overall response rates (ORRs) and complete response rates (CRs) of 83% and 58%, respectively, with a median follow-up of 27.1 mo[5]. However, durable complete responses (CRs) are approximately 30% to 40%, indicating that the majority of patients treated with CAR-T cells ultimately progress[6,7]. Unfortunately, there are few appropriate treatment options for patients who develop progressive disease (PD) after CAR-T cell treatment and their median overall survival is only approximately 5 mo[6].

Immune checkpoint inhibitors, especially PD-1 inhibitors, have shown encouraging clinical efficacy in R/R B-cell lymphomas[8]. Recently, Chonget al[9] reported that a patient with R/R DLBCL who developed PD after treatment with CD19-specific CAR-T cells had a significant response following PD-1 blockade therapy. In addition, some recent studies have suggested that patients with large B-cell lymphoma who develop progressive disease after treatment with CD19-specific CAR-T cells may benefit from checkpoint-based therapy[6,7]. Of note, PD-1 inhibitor monotherapy is associated with a low overall response rate among patients with R/R DLBCL which may limit its widespread use in clinical experience[10].

Chidamide is a novel oral selective histone deacetylase inhibitor (HDACi) approved in China for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). Previous studies have shown that HDAC increases tumor antigen presentation, reduces immunosuppressive cell types and augments checkpoint inhibitor therapy[10]. Additionally, chidamide induces growth arrest and apoptosis of lymphogenic tumor cells and enhances antitumor immunity by activating NK cells and CD8+cytotoxic T cells[12,13]. Furthermore, a recent study showed that chidamide may augment the efficacy of PD-1 inhibitors in soft tissue sarcoma[14]. Therefore, the combination of chidamide and PD-1 inhibitors might be an important option for PD patients post CAR-T cell therapy.

In the present study, we report on seven patients who developed PD after CD19-targeted CAR-T therapy. They received treatment with chidamide (Chipscreen Bioscience Ltd, Shenzhen, China) and sintilimab (Innovent Biologics, Suzhou, China), which had not been reported previously.

CASE PRESENTATlON

Chief complaints

In this study, we performed a retrospective analysis of an R/R B-cell lymphoma cohort of 7 DLBCL patients with disease progression after CD19-targeted CAR-T therapy. This study was approved by the Medical Ethics Committee of the First Affiliated Hospital of Zhejiang University School of Medicine. The median age of the 7 patients was 55 years (range 46-68) and 4 of the 7 patients were female.

History of present illness

All patients were diagnosed with DLBCL (nonGCB), including one patient who had follicular lymphoma (grade 3B) that transformed to DLBCL.

History of past illness

One patient (14.3%) relapsed after autologous hematopoietic cell transplantation before CAR-T therapy. All patients received lymphodepletion chemotherapy consisting of cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) for 3 d before CAR-T infusion. The indications for CAR-T cell therapy were as follows: no response to CAR-T cells (n= 3, 42.9%), relapse or progression after initial PR (n= 2, 28.6%), and relapse or progression after initial CR (n= 2, 28.6%). The median time from CAR-T to treatment with chidamide and sintilimab therapy was 4 mo. Four patients were positive for PD-L1 expression on tumor cells (range, 3-10%), and three were negative before chidamide and sintilimab treatment. Three patients (42.9%) received bridging therapy before chidamide and sintilimab treatment. These bridging chemotherapies included GDP (gemcitabine, dexamethasone, cisplatin) and ICE (ifosfamide, carboplatin, and etoposide).

Personal and family history

No specific personal and family history.

Physical examination

The Eastern Cooperative Oncology Group (ECOG) score of the 7 patients is showed in Table 1.

Laboratory examinations

No additional laboratory examinations were performed on the 7 patients.

Imaging examinations

After 5 courses of treatment, PET-CT showed continued partial response (PR) with only a little hypermetabolism in the testes.

FlNAL DlAGNOSlS

7 DLBCL patients with disease progression after CD19-targeted CAR-T therapy.

TREATMENT

This novel therapy comprises chidamide (30 mg orally twice per week) and sintilimab (200 mg every 3 wk). Adverse events (AEs) of chidamide and sintilimab mainly included thrombocytopenia, leucopenia, neutropenia and fatigue[13]. All patients experienced treatment-related AEs of any grade during the treatment and five of the patients tolerated the AE’s. Two of the patients developed severe treatmentrelated AEs including lung infection and rash. Therefore, they discontinued treatment despite having a better therapeutic effect. Nevertheless, one of these two patients remained in CR 1 year after stopping treatment, and the other patient developed PD 8 mo after stopping treatment. No patient died from the treatment-related AEs. Five of the seven patients died due to disease progression. Based on the safety profile of these seven patients, the regimen was deemed a safe study protocol.

OUTCOME AND FOLLOW-UP

Four of the seven patients (57.1%) achieved objective response within 2 courses of chidamide and sintilimab therapy, and two of them achieved CR within 4 and 5 courses, respectively. The median progression-free survival (PFS) and OS were 4 and 6 mo, respectively (Figures 1 and 2). Among all patients (Figure 3), 2 patients had persistent treatment-related AEs during the treatment period at the last follow-up. One patient was a 60-year-old male with R/R DLBCL (nonGCB, IV B, IPI 4). He underwent fludarabine-cyclophosphamide lymphodepletion followed by infusion of CD19-targeted CAR-T cells after relapsing on 3 prior treatments. He tolerated the treatment without CRS and ICANS. However, on day +90, PET-CT showed his PD. He received ICE treatment but could not tolerate it. Then, we treated him with chidamide and sintilimab. After 2 courses of treatment, he had PR. After 5 courses of treatment, PET-CT showed continued PR with only a little hypermetabolism in the testes (Figure 4). After 6 mo, he probably reached CR due to the absence of enlarged lymph nodes on ultrasound. However, due to a serious lung infection, he stopped treatment after 8 mo, and he received no additional treatment for his disease. To our surprise, 1 year after he stopped the treatment, he was still alive and felt well with no PD. The other patient was a 48-year-old female with R/R DLBCL (nonGCB, IIA, IPI 2) for 2.5 years. She had received 4 prior chemotherapies, including autoHSCT, before CD19 CAR-T. Biopsy of the breast mass confirmed DLBCL with CD19 and PD-L1 (10%) expression. She underwent standard lymphodepletion and CD19 CAR-T. She did not develop any CRS or ICANS. PET-CT revealed PR on day +30 and CR on day +90. However, after 15 mo, CT revealed PD. Then, she received chidamide and sintilimab therapy. After 4 courses, she had a PR on ultrasound. However, due to serious mouth ulcers and rash, she stopped the treatment after 4 mo. Since then, she did not undergo further treatment. Unfortunately, 8 mo later, she had PD on PET-CT.

Table 1 The disease characteristics of 7 patients

DlSCUSSlON

Figure 1 The progression-free survival of the 7 patients. PFS: progression-free survival.

Figure 2 The overall survival of the 7 patients.

Figure 3 Treatment response of each patient and the duration of response after treatment with sintilimab and chidamide.

To date, four CD19-CAR-T products have been approved by the US Food and Drug Administration (FDA) as treatments for R/R B-cell lymphomas, including 4-1BB-based axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel (liso-cel), and CD28-based KTE-X19[3,5,15,16]. Nastoupilet al[17] reported at a median follow-up of 12.9 mo that axi-cel in 275 R/R LBCL patients treated with standard therapy exhibited ORRs and CRs of 82% and 64%, respectively. Recent data show that the 5-year ORR of patients with R/R B-cell lymphoma treated with CD19-targeted CAR-T cells (tisagenlecleucel) was 58%, and 46% had CR[18]. Despite the efficacy of CAR-T therapy in patients with R/R DLBCL, approximately 50% of patients still experience PD after CAR-T therapy[7]. For these patients, the median OS was only 5.3 mo and treatment options remain limited[6].

Three reasons for nonresponse or relapse in patients receiving CD19-targeted CAR-T infusions are (1) loss or downregulation of CD19 expression; (2) poor T-cell function; and (3) immune-suppressed tumor microenvironment. In the ZUMA-1 study, 4 of 16 patients (25%) relapsed post-CAR-T (axi-cel) due to loss of CD19 expression[19]. In a large cohort of 136 patients who had PD after CAR-T infusion, CD19 loss accounted for approximately 30% of progression cases[7]. Poor T-cell function is another reason explaining the failure of CAR-T therapies. A study found that many patients had insufficient CAR-T expansion capacity, suggesting that intrinsic causes of T cells contribute to treatment failure[20]. Recently, many studies have found that the tumor microenvironment (TME) plays an important role in cancer progression and therapy resistance. In the TME, tumor-derived extracellular vesicles (TEXs) act as communication vehicles to transfer information between cancer cells and other cells and their unique functions have gained increasing attention such as, promoting tumorigenesis and metastasis, modulating antitumor immunity and neutralizing drugs to compromise therapeutic effects[21,22]. Immunosuppressive molecules carried by TEXs can inhibit T cells and CAR-T cells.

Figure 4 The positron emission tomography-computed tomography scans before and during the combined treatment of the patient 3.

Salvage therapies post axi-cel include checkpoint inhibitors, lenalidomide, chemotherapy, radiation, venetoclax, ibrutinib or a second CAR-T. Among these salvage therapies, checkpoint inhibitor-based therapy appears to be the most effective treatment, with an ORR of 46% and CR of 18%[7]. Of note, an alternative CD19-targeted CAR-T therapy for disease progression after the first CD19-CAR-T therapy may have a limited response. Chowet al[6] reported 3 patients with R/R DLBCL whose disease progressed after CD19-CART therapy who were treated with an alternative CD19-CAR-T product for salvage treatment. The dates of PD in these three patients were +160, +21 and +6 d after the second CD19 CAR-T infusion, respectively. This result shows that no meaningful responses were observed with salvage therapy using alternative CD19-CAR-T products.

In our study, there were 2 CRs and 2 PRs during this novel therapy, with an ORR of 57.1% and CR of 28.6%. One patient had a durable CR that lasted at least 20 mo, which may be slightly better than other therapies. Anti-PD-1/PD-L1 immunotherapy has emerged as a new treatment option for R/R lymphoma, especially in combination with other drugs. Of note, in our study, PD-L1 expression was 10% and 0% in the 2 patients who achieved CR, indicating that higher tumor PD-L1 expression might not be necessary for effective chidamide plus sintilimab combination therapy. Chidamide, a subtypeselective HDACi, not only directly exerts anticancer activity but also exerts multiple immunomodulatory effects. On the one hand, it enhances the antitumor ability of immune cells by enhancing the intratumoral infiltration of CD8+T cells and macrophages, upregulating costimulatory molecules, promoting tumor-specific T cell-mediated cancer cell killing and sensitizing tumor cells to NK cell lysis. On the other hand, it inhibits intratumoral infiltration of myeloid-derived suppressor cells (MDSCs), primary M2 macrophages and T-regulatory cells[23-25]. HDACis may also enhance checkpoint inhibitor therapy. Yanet al[26] reported that a patient with NK/T-cell lymphoma resistant to pegaspargase and immunotherapy had a durable response to sintilimab and chidamide. Currently, a clinical trial is evaluating the feasibility of combination therapy with HDACis and PD1 inhibitors[27].

One limitation of our study is the small number of patients in our single-center experience. Another limitation is that the choice of therapy may be influenced by multiple factors such as physician preference, cost, the proximity of treatment centers and even coronavirus disease 2019[28], which may influence therapeutic effects and disease assessment. Future studies should incorporate multicenter cohorts and randomized clinical studies.

CONCLUSlON

In summary, the outcome after PD of CD19-targeted CAR-T therapy is poor. Despite the limited number of meaningful responses observed, chidamide and sintilimab may be salvage treatment options. To our knowledge, this is the first report on the outcome of chidamide and sintilimab treatment in patients with PD following CD19-specific CAR-T therapy. These data may inform novel interventions for the treatment of this group of patients.

FOOTNOTES

Author contributions:Hao YY conceived the study, analyzed data and drafted the manuscript; Chen PP and Yuan XG collected and analyzed data; Zhao AQ, Liang Y and Liu H reviewed the manuscript; Qian WB supported the study technically and reviewed the manuscript; all authors read and approved the final manuscript.

lnformed consent statement:All involved persons gave their informed consent (verbal) prior to study inclusion.

Conflict-of-interest statement:The authors declare no competing interests.

CARE Checklist (2016) statement:The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access:This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BYNC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin:China

ORClD number:Yuan-Yuan Hao 0000-0003-4601-8102; Pan-Pan Chen 0000-0002-7114-6352; Xiang-Gui Yuan 0000-0003-0920-6171; Ai-Qi Zhao 0000-0001-8319-9454; Yun Liang 0000-0002-9215-1708; Hui Liu 0000-0003-1452-5062; Wen-Bin Qian 0000-0002-9817-6674.

S-Editor:Wu YXJ

L-Editor:Filipodia

P-Editor:Wu YXJ